New Drug Development Services
In vivo tumor experimental platform
Welcome to learn about our in vivo tumor experimental platform, which is specifically designed for preclinical research on tumors and tumor immunotherapy. Our platform integrates a series of advanced technologies and experimental methods, aiming to provide researchers with the most comprehensive and realistic drug evaluation environment.
Platform Features:
•CDXTraditional patient-derived tumor xenograft models used to evaluate the efficacy and anti-tumor activity of drugs.
•SyngeneicSyngeneic models use immunocompetent mice to establish syngeneic transplant models of mouse-derived tumors. Because these mice have a fully natural immune system, they become an ideal choice for testing various immunotherapies. This model can provide immune response data that is closer to clinical situations.
•iHuPDXHumanized patient-derived tumor xenograft models that are closer to the real human environment, providing higher accuracy for drug evaluation.
•In situ surgical models:
•Brain in situ modelsSimulate the growth and treatment response of brain tumors, providing key data for central nervous system drug evaluation.
•Others in situ modelsSimulate the growth and treatment response of tumors in other organs, covering a wide range of tumor types.
•Hematologic tumor systemic inoculationSpecifically designed to evaluate the growth and treatment response of hematologic tumor cells after intravenous inoculation, providing key data for hematologic tumor treatment strategies.
Our in vivo tumor experimental platform combines various advanced technologies to provide comprehensive support for your tumor and tumor immunotherapy research. If you have any questions or need further information, please feel free to Contact Us.